Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant

Nagase, Kazuko; Fukunaga, Ken; Ohnishi, Kunio; Kusaka, Takeshi; Matoba, Yoshika; Sawada, Koji

doi:10.1111/j.1526-0968.2004.00086.x

Cited by 16 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In such perspective, the rate of AR cannot simply be compared with other studies including all PE sessions. The AR seen in this study may reflect reactions not only to FFP but also to other components of TPE, such as anticoagulation drugs [5] and materials used in the extracorporeal circuit [6]. Our analysis cannot differentiate the cause of AR.…”

Section: Discussionmentioning

confidence: 79%

Risk factors for allergic reaction at initial therapeutic plasma exchange in a single-center study: beware of high rates of severe allergic reaction

et al. 2016

View full text Add to dashboard Cite

Background: Therapeutic plasma exchange (TPE) is an important treatment modality for various diseases, but its use can be restricted by allergic reactions (AR). The aim of our study was to elucidate the frequency of and risk factors for AR at initial TPE using fresh frozen plasma (FFP).Methods: Presences of AR were extracted from the medical records of consecutive patients receiving TPE from 2002 to 2012. The following data at initial TPE were retrieved: age, gender, history of allergy, steroid use, timing of steroid use, mean steroid dose, immunosuppressant use, indication for TPE, and laboratory data.Results: Eighty-eight patients (median age 57 years) underwent TPE, and 28% had an episode of AR. Younger age (odds ratio (OR), 1.04 (95% CI, 1.01-1.08)) and indications other than hepatic insufficiency (OR, 17.8 (95% CI, 1.95-429.4)) were associated with higher incidence of AR.Conclusions: Close observation for AR may be warranted at initial TPE for these conditions.

show abstract

Section: Discussionmentioning

confidence: 79%

Risk factors for allergic reaction at initial therapeutic plasma exchange in a single-center study: beware of high rates of severe allergic reaction

et al. 2016

View full text Add to dashboard Cite

show abstract

“…An optimum dose of sodium heparin (2,000 units/session) as an anticoagulant was administered during both GMA and the sham procedures. Nafamostat mesilate (a common anticoagulant during leucocytapheresis in Japan) was avoided as this substance is associated with allergic reactions 8. The Sham GMA was based on the design by Sands et al,9 having the circuit blood lines without the Adacolumn itself.…”

Section: Methodsmentioning

confidence: 99%

Adsorptive Granulocyte/Monocyte Apheresis for the Maintenance of Remission in Patients with Ulcerative Colitis: A Prospective Randomized, Double Blind, Sham-Controlled Clinical Trial

Fukunaga¹,

Yokoyama²,

Kamokozuru³

et al. 2012

Gut Liver

Self Cite

View full text Add to dashboard Cite

Background/AimsWeekly granulocyte/monocyte adsorption (GMA) to deplete elevated and activated leucocytes should serve as a non-pharmacological intervention to induce remission in patients with ulcerative colitis (UC). This trial assessed the efficacy of monthly GMA as a maintenance therapy to suppress UC relapse.MethodsThirty-three corticosteroid refractory patients with active UC received 10 weekly GMA sessions as a remission induction therapy. They were then randomized to receive one GMA session every 4 weeks (True, n=11), extracorporeal circulation without the GMA column every 4 weeks (Sham, n=11), or no additional intervention (Control, n=11). The primary endpoint was the rate of avoiding relapse (AR) over 48 weeks.ResultsAt week 48, the AR rates in the True, Sham, and Control groups were 40.0%, 9.1%, and 18.2%, respectively. All patients were steroid-free, but no statistically significant difference was seen among the three arms. However, in patients who could taper their prednisolone dose to <20 mg/day during the remission induction therapy, the AR in the True group was better than in the Sham (p<0.03) or Control (p<0.05) groups.ConclusionsMonthly GMA may potentially prevent UC relapse in patients who have achieved remission through weekly GMA, especially in patients on <20 mg/day PSL at the start of the maintenance therapy.

show abstract

“…Nafamostat mesilate (NM) is recognized in Japan as an effective anticoagulant (15), but there is also a risk of an anaphylactic reaction triggered by anti-NM antibodies (16,17). We experienced a case of a 20-year-old female who had taken NM as an anticoagulant during two previous series of LCAP.…”

Section: T Ishihara Et Al 592mentioning

confidence: 99%

Adverse Events in Therapeutic Apheresis: A Single Center Survey of Various Therapies

Ishihara¹,

Inoue²,

Takagi³

et al. 2010

Ther Apher Dial

View full text Add to dashboard Cite

The aim of the study was to review the adverse events associated with various treatment modalities performed in a single apheresis facility. A total of 854 sessions with 10 types of apheresis therapies were performed and 154 (18.0%) adverse events were observed over a four-year period. Of the adverse events, 77 were related to operational problems and another 77 were complications associated with treatment. A transmembranous pressure abnormality constituted more than 80% of the operational problems. Nausea was the most frequent complication, accounting for 19 of the 77 treatment-related events. A total of 26 (16.9%) adverse events occurred in the early stage of the sessions, 40 (26.0%) in the middle stage, and 88 (57.1%) in the late stage. The information in this study can be used to improve the safety and efficacy of apheresis therapy.

show abstract

Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant

Cited by 16 publications

References 24 publications

Risk factors for allergic reaction at initial therapeutic plasma exchange in a single-center study: beware of high rates of severe allergic reaction

Risk factors for allergic reaction at initial therapeutic plasma exchange in a single-center study: beware of high rates of severe allergic reaction

Adsorptive Granulocyte/Monocyte Apheresis for the Maintenance of Remission in Patients with Ulcerative Colitis: A Prospective Randomized, Double Blind, Sham-Controlled Clinical Trial

Adverse Events in Therapeutic Apheresis: A Single Center Survey of Various Therapies

Contact Info

Product

Resources

About